The data from the Phase III LUNAR trial, which assessed the device’s treatment efficacy and safety, supported the approval.

Vivasure hope to find room in a competitive market with its surtureless implant that is absorbed 180 days after vessel ...

The regulatory approval in the EU comes approximately six months after Novocure secured FDA approval of the system.

Vivasure Medical announced today that it received CE mark approval for its PerQseal Elite vascular closure system.

Novocure (NVCR) announced that Optune Lua has received a CE Mark for the treatment of adult patients with metastatic non-small cell lung cancer ...

Basel: Roche has announced the introduction of its Chest Pain Triage algorithm as part of the navify Algorithm ...

Optune Lua received a CE Mark for metastatic non–small cell lung cancer with immune checkpoint inhibitors or docetaxel.

“The CE Mark approval for Optune Lua for metastatic non-small cell lung cancer is a significant milestone in Novocure’s efforts to improve outcomes for people living with aggressive cancers ...

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...

Novocure has obtained CE Mark approval for its Optune Lua device to treat adults with metastatic non-small cell lung cancer (NSCLC) simultaneously with immune checkpoint inhibitors or docetaxel.